Thrivent Financial for Lutherans Trims Position in IQVIA Holdings Inc. (NYSE:IQV)

Thrivent Financial for Lutherans reduced its position in IQVIA Holdings Inc. (NYSE:IQV) by 12.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 37,742 shares of the medical research company’s stock after selling 5,435 shares during the quarter. Thrivent Financial for Lutherans’ holdings in IQVIA were worth $7,417,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Smith Group Asset Management LLC purchased a new stake in IQVIA in the 4th quarter worth approximately $1,616,000. Nordea Investment Management AB increased its holdings in shares of IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after purchasing an additional 452,029 shares during the period. Hickory Asset Management Inc. purchased a new stake in shares of IQVIA in the fourth quarter worth $941,000. Fifth Third Bancorp boosted its stake in IQVIA by 13.0% during the fourth quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock valued at $2,590,000 after buying an additional 1,521 shares during the period. Finally, Graphene Investments SAS increased its stake in IQVIA by 22.0% in the 4th quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company’s stock worth $2,948,000 after acquiring an additional 2,700 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Royal Bank of Canada reiterated an “outperform” rating and set a $270.00 price target on shares of IQVIA in a research report on Monday, February 10th. Bank of America lowered their price objective on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Robert W. Baird dropped their price objective on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, January 21st. Barclays reduced their target price on IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. Finally, BTIG Research cut IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. Five research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Price Performance

Shares of IQVIA stock opened at $185.85 on Monday. The firm has a market cap of $32.77 billion, a PE ratio of 24.78, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The company’s fifty day simple moving average is $194.94 and its two-hundred day simple moving average is $208.16. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 12-month low of $179.28 and a 12-month high of $254.54.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, equities analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.